Ledraxen (Enoxaparin Sodium)

Ledraxen is a low molecular weight heparin used in the prevention and treatment of venous thrombo‑embolic disorders.

• Prevention of deep vein thrombosis (DVT) in surgical patients: reduces the incidence of postoperative clot formation.
• Treatment of acute deep vein thrombosis: facilitates clot resolution and prevents propagation.
• Prevention and treatment of pulmonary embolism: provides anticoagulation to lower the risk of embolic events.
• Anticoagulation during haemodialysis: maintains circuit patency by inhibiting clot formation.

• Enoxaparin sodium potentiates antithrombin III, enhancing its inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This selective blockade reduces thrombin generation and fibrin clot formation, thereby providing anticoagulant protection without markedly affecting platelet function.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects

• Injection‑site bruising or pain: mild local irritation at the administration site.
• Minor bleeding: such as epistaxis, gum bleeding or easy bruising.
• Nausea or gastrointestinal discomfort: occasional transient upset.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Major bleeding: internal hemorrhage including gastrointestinal or intracranial bleeding.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet decline with paradoxical thrombosis.
• Spinal or epidural hematoma: risk when combined with neuraxial anesthesia.
• Severe allergic reaction: anaphylaxis, urticaria or angioedema.
• Paradoxical thrombosis: clot formation despite therapy.

Careful assessment and monitoring are required when using enoxaparin.

• Renal function: adjust dose or avoid use in severe renal impairment.
• Platelet count: monitor regularly for thrombocytopenia, especially after 5‑10 days.
• Concomitant anticoagulants: avoid or use with caution to reduce bleeding risk.
• Active bleeding: contraindicated in patients with ongoing hemorrhage.
• Surgical procedures: discontinue appropriately before neuraxial or invasive surgery.
• Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Enoxaparin may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increase bleeding risk.
• Antiplatelet agents (e.g., aspirin, clopidogrel): additive antithrombotic effect.
• Thrombolytic therapy (e.g., alteplase): synergistic hemorrhagic potential.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding.
• Neuraxial anesthesia or spinal puncture: risk of spinal hematoma.

Moderate Interactions (Monitor Closely)

• Certain antibiotics (e.g., vancomycin, quinolones): may alter anticoagulant activity.
• ACE inhibitors or ARBs: potential for enhanced anticoagulant effect.
• Diuretics: may affect plasma volume and drug concentration.
• Hormonal contraceptives or hormone replacement therapy: modest increase in thrombotic risk.
• Lipid‑lowering agents (e.g., statins): occasional impact on platelet function.